ArticleRespiratory research2026
HDAC6 inhibition reprograms endothelial and macrophage responses to protect the lung in endotoxemia.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEndotoxemia causes pulmonary barrier disruption, endothelial dysfunction, and myeloid-mediated inflammatory responses leading to sepsis-associated acute lung injury. Histone deacetylase 6 (HDAC6) regulates cytoskeletal dynamics and inflammatory signaling; however, its cell-type-specific effects in inflammatory lung injury remain undetermined.
methodsWe conducted single-cell RNA sequencing in a mouse endotoxemia model to investigate the effects of HDAC6 inhibition on endothelial and macrophage responses. Key findings were confirmed using histology and bulk RNA sequencing studies.
resultsIn endothelial cells, lipopolysaccharide induced inflammation and STAT pathway activation. HDAC6 inhibition with CAY10603 suppressed these changes, lowered inflammatory and apoptotic scores, and maintained endothelial cells toward earlier pseudotime states. Concurrently, HDAC6 inhibition via CAY10603 treatment restored angiogenesis-associated gene expression (Acadl, Adrb2, Cd24a, Ecm1, and Ptgs1). In macrophages, CAY10603 treatment suppressed lipopolysaccharide-induced interferon, inflammasome, and IL-6/JAK/STAT3 signatures and downregulated key gene expression (Isg15, Ifit1/2, Lcn2, Txnip, and Irf1), maintaining them in less activated states. These findings correlated with reduced alveolar congestion and leukocyte infiltration and suppressed inflammation signatures.
conclusionsSelective HDAC6 inhibition suppresses endothelial activation and macrophage inflammatory programs while promoting angiogenic transcriptional programs, supporting further evaluation of HDAC6-targeted strategies for sepsis-associated lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.